Repository logo
 
Publication

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update

2022-06-11Journal article Open access
Simple item page
dc.contributor.authorSacco, Simona
dc.contributor.authorAmin, Faisal Mohammad
dc.contributor.authorAshina, Messoud
dc.contributor.authorBendtsen, Lars
dc.contributor.authorDeligianni, Christina I.
dc.contributor.authorGil-Gouveia, Raquel
dc.contributor.authorKatsarava, Zaza
dc.contributor.authorMaassenVanDenBrink, Antoinette
dc.contributor.authorMartelletti, Paolo
dc.contributor.authorMitsikostas, Dimos Dimitrios
dc.contributor.authorOrnello, Raffaele
dc.contributor.authorReuter, Uwe
dc.contributor.authorSanchez-del-Rio, Margarita
dc.contributor.authorSinclair, Alexandra J.
dc.contributor.authorTerwindt, Gisela
dc.contributor.authorUluduz, Derya
dc.contributor.authorVersijpt, Jan
dc.contributor.authorLampl, Christian
dc.date.accessioned2022-06-24T08:23:35Z
dc.date.available2022-06-24T08:23:35Z
dc.date.issued2022-06-11
dc.description.abstractBackground: A previous European Headache Federation (EHF) guideline addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway to prevent migraine. Since then, randomized controlled trials (RCTs) and real-world evidence have expanded the evidence and knowledge for those treatments. Therefore, the EHF panel decided to provide an updated guideline on the use of those treatments. Methods: The guideline was developed following the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. The working group identified relevant questions, performed a systematic review and an analysis of the literature, assessed the quality of the available evidence, and wrote recommendations. Where the GRADE approach was not applicable, expert opinion was provided. Results: We found moderate to high quality of evidence to recommend eptinezumab, erenumab, fremanezumab, and galcanezumab in individuals with episodic and chronic migraine. For several important clinical questions, we found not enough evidence to provide evidence-based recommendations and guidance relied on experts’ opinion. Nevertheless, we provided updated suggestions regarding the long-term management of those treatments and their place with respect to the other migraine preventatives. Conclusion: Monoclonal antibodies targeting the CGRP pathway are recommended for migraine prevention as they are effective and safe also in the long-term.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.1186/s10194-022-01431-xpt_PT
dc.identifier.eid85131902488
dc.identifier.issn1129-2369
dc.identifier.pmcPMC9188162
dc.identifier.pmid35690723
dc.identifier.urihttp://hdl.handle.net/10400.14/37962
dc.identifier.wos000809558400001
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCalcitonin gene-related pathwaypt_PT
dc.subjectGuidelinept_PT
dc.subjectMigrainept_PT
dc.subjectMonoclonal antibodiespt_PT
dc.subjectPreventionpt_PT
dc.titleEuropean Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 updatept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue1pt_PT
oaire.citation.titleJournal of Headache and Painpt_PT
oaire.citation.volume23pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
45140991.pdf
Size:
1.39 MB
Format:
Adobe Portable Document Format
Download

Collections

CIIS - Contribuições em Revistas Científicas / Contribution to Journals